<DOC>
	<DOCNO>NCT01529073</DOCNO>
	<brief_summary>Objectives : 1 . Primary objective : To Evaluate rate sustain virological response ( SVR ) pegylated interferon alfa-2b ( Peg-IFN ) plus ribavirin ( RBV ) plus nitazoxanide ( NTZ ) patient coinfected HIV HCV genotype 4 ( HCV-4 ) , never treat ( naïve ) treatment failure standard therapy Peg-IFN plus RBV ( experience ) , compare rate SVR patient Peg-IFN plus RBV historical cohort . 2 . Secondary objective : In naive , well experienced patient : ) To evaluate virological activity week 4 12 start combination Peg-IFN plus RBV plus NTZ HIV/HCV-4-coinfected patient . b ) To analyze safety Peg-IFN plus RBV plus NTZ HIV/HCV-4-coinfected patient . Design : Pilot clinical trial without control evaluate efficacy safety ( phase II ) . Patients : Individuals HIV infection confirm chronic HCV infection . Treatment : NTZ 500 mg every 12 hour 4 week , follow NTZ 500 mg every 12 hour plus Peg-IFN plus weigh-adjusted RBV 48 week . Total duration therapy : 52 week . Primary variable : The proportion patient HCV RNA ≤10 IU/ml 24 week finish programmed length treatment . Secondary variable : 1 . The frequency individual HCV RNA ≤10 IU/ml 12 week finish programmed length treatment . 2 . The proportion patient HCV RNA ≤10 IU/ml 4 12 week add PegIFN plus RBV NTZ . 3 . The frequency severe adverse event .</brief_summary>
	<brief_title>Efficacy Pegylated Interferon Plus Ribavirin Plus Nitazoxanide HCV Genotype 4 HIV Coinfection</brief_title>
	<detailed_description>Main Objective To evaluate SVR rate treatment Peg-IFN alfa-2b plus RBV NTZ patient coinfected HIV HCV genotype 4 , never expose therapy HCV fail previous treatment Peg-IFN plus RBV , compare SVR rate obtain patient Peg-IFN plus RBV historical cohort . Secondary objective : In naive , well experienced patient : 1 . To evaluate virological activity week 4 12 start combination Peg-IFN plus RBV plus NTZ HIV/HCV-4-coinfected patient . 2 . To analyze safety Peg-IFN plus RBV plus NTZ HIV/HCV-4-coinfected patient . Design Single arm pilot clinical trial evaluate safety efficacy ( phase II ) . Disease disorder study Coinfection HIV HCV genotype 4 . Drugs study Nitazoxanide 500 mg every 12 hour 4 week follow nitazoxanide 500 mg every 12 hour plus pegylated interferon alfa-2b 1.5 mcg/kg/week weight-adjusted ribavirin 48 week . Study Population total number subject Patients infect HIV-1 chronic HCV genotype 4 meet selection criterion . Number patient include study : 45 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<criteria>1 . HIV infection . 2 . Infection HCV genotype 4 . 3 . No prior treatment interferon response previous treatment PegIFN plus RBV . The lack response include nonresponders , show relapse . 4 . Stable antiretroviral therapy 24 week start study drug , undetectable plasma HIV RNA period time . 5 . Commitment use two nonhormonal contraception study 24 week treatment . 6 . Acceptance give write informed consent participate trial . 1 . Antiretroviral therapy include didanosine , stavudine , zidovudine abacavir . 2 . Decompensated cirrhosis . 3 . Presence significant liver disease , include chronic hepatitis acute hepatitis B , acute hepatitis hepatitis A , hemochromatosis deficiency alpha1 antitrypsin . 4 . Pregnancy lactation . 5 . Men plan pregnancy partner study 24 week treatment . 6 . Active uncontrolled depression , psychiatric illness , disease previous year may , investigator 's opinion , prevent participation study . 7 . Previous suicide attempt . 8 . Active thyroid disease poorly control treatment . 9 . Previous autoimmune disease inflammatory bowel disease , psoriasis serious , rheumatoid arthritis , may exacerbate interferon . 10 . Chemotherapy immunomodulatory 24 week start study . 11 . Serious illness , include cancer unstable coronary disease , 24 week start study . 12 . Any chronic disease , opinion investigator , may prevent complete study . 13 . Presence acute active opportunistic infection 48 week start study . 14 . Evidence hepatocellular carcinoma alphafetoprotein level ≥ 50 ng / ml , unless image technique show evidence liver tumor , obtain 24 week start study . 15 . Hemoglobinopathy condition may facilitate hemolysis . 16 . Solid organ bone marrow transplant . 17 . Known hypersensitivity drug study . 18 . Active consumption drug alcohol opinion investigator would interfere participation study . The use methadone opiate replacement therapy consider exclusion criterion . 19 . Serious side effect treatment PegIFN plus RBV patient prior failure treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>genotype 4 HCV</keyword>
	<keyword>pegylated interferon</keyword>
	<keyword>ribavirin</keyword>
	<keyword>nitazoxanide</keyword>
</DOC>